OGI Stock Analysis: Buy, Sell, or Hold?
OGI - Organigram Global Inc. Common Shares
$0.90
-0.07 (-7.32%)
▼
5d:
-9.4%
30d:
-15.49%
90d:
-36.01%
HOLD
LOW Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 12, 2026
28d
Get Alerted When OGI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: OGI shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: OGI shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: OGI is currently trading at $0.90, which is considered oversold relative to its 30-day fair value range of $0.96 to $1.06. From a valuation perspective, the stock is trading at a discount (Forward PE: 40.7) compared to its historical average (61.5). Remarkably, the market is currently pricing in an annual earnings decline of 12.9% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, OGI is in a strong downtrend. The price is currently testing key support at $1.06. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.3% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.80 (+882.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, OGI is in a strong downtrend. The price is currently testing key support at $1.06. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.3% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.80 (+882.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.96 -
$1.06
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.3%)
- BULLISH: Trading 882.4% below Wall St target ($8.80)
- CAUTION: Recommendation downgraded due to -9.4% 5-day decline
Trading Range Analysis
30-Day Trading Range
$0.96 -
$1.06
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.06
Resistance Level
$1.21
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
40.72
Wall Street Target
$8.80
(+882.4%)
Revenue Growth (YoY)
-8.9%
Profit Margin
-9.2%
Valuation Discount vs History
-12.9% cheaper
PE vs Historical
40.7 vs 61.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-12.9%
(market-implied from PE analysis)
1-Year Target
$0.81
(-10%)
2-Year Target
$0.73
(-19%)
3-Year Target
$0.65
(-27%)
3-Yr Target (if PE normalizes)
(PE: 41→62)
$0.99
(+10%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 40.7, Growth: -66.7%)
$0.65
(+-27%)
Base:
(SPY PE: 21.8, Growth: -66.7%)
$0.35
(-61%)
Bear:
(PE: 18.5, Growth: -66.7%)
$0.30
(-67%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 40.7 to 61.5
Stabilization Target:
$1.35
(+51.0%)
PE Expansion Potential:
+51.0%
Share & Embed Analysis
Last updated: July 14, 2026 2:08 AM ET
Data refreshes hourly during market hours. Next update: 3:08 AM
Data refreshes hourly during market hours. Next update: 3:08 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OGI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$198 | 67 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$116 | 59 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$110 | 51 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 55 HOLD |
